Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

Dr Daniel Rosen, who is a surgeon and obesity medicine specialist based out of New York, says a 'legitimate number' of his ...

Drugs like Ozempic, Wegovy and Mounjaro are changing the game for weight loss. GLP-1 medications were originally intended to treat type 2 diabetes, but a growing number of people are using it for ...

Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...

In a live taping of "The Readout LOUD" at #JPM25, Eli Lilly CEO Dave Ricks talks Trump, Medicare's drug price negotiation, ...

In a new report, global health experts are urging that we redefine the measurements used to determine whether someone is ...

Pharmacy professor Nicole Albanese discusses the science behind drugs like Ozempic and Wegovy, their potential to treat other ...

Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.

Eli Lilly and Company’s LLY shares declined 6.6% on Tuesday after the company lowered its sales guidance for full-year 2024 ...

Calling people obese is medically "flawed" - and the definition should be split into two, a report from global experts says.

When drugmakers pulled the weight-loss drug fen-phen off the market in 1997, my mom was devastated. Not because the FDA ...

Concerned about fatty liver? Discover five signs you can easily check at home, as described by liver specialist Dr. Saurabh ...